#95 Landmark Clinical Evidence
Peer-reviewed human research with direct implications for cannabis medicine practice.
🏥 While legal status and regulatory frameworks governing cannabis continue to evolve across jurisdictions, clinicians should recognize that legal availability does not necessarily equate to clinical safety or evidence-based therapeutic benefit. The patchwork of state and federal regulations creates confusion for both patients and providers about what constitutes appropriate medical use, quality standards, and potential drug interactions, particularly since cannabis remains classified as a Schedule I substance federally despite legalization in many states. Importantly, patient beliefs about legality may inappropriately reassure them regarding risk—including impaired driving, cognitive effects, and cannabis use disorder—while the lack of FDA oversight means product potency and contaminant profiles are highly variable. Clinicians should maintain an evidence-based approach by discussing documented risks and benefits with patients regardless of local legal status, documenting cannabis use in the medical record, and being aware of potential interactions with medications metabolized through the CYP3A4 and CYP
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it:
